Harbour BioMed

Cambridge, Massachusetts, September 9, 2026 Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001...

Shanghai, China, September 10, 2026 Solstice Oncology, a partner of Harbour BioMed, has announced a $225 million Series A...

Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...

Cambridge, MA, Rotterdam, Netherlands, and Shanghai, China – July 27, 2026 Harbour BioMed has entered into a strategic collaboration...

NEW YORK, June 15, 2026 Enhanced Group Inc. has announced a $50 million strategic equity financing through a private...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SHANGHAI, China, June 15, 2026 Harbour BioMed and BioMap have announced a long-term strategic...

CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...

CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; SHANGHAI, China, June 10, 2026 Harbour BioMed announced that the National Medical Products Administration (NMPA)...

CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; and SHANGHAI, China, May 18, 2026 Harbour BioMed announced promising preclinical data for LET003, its...

CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, May 8, 2026 Harbour BioMed announced that the U.S. Food and Drug...